Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)—Polish compassionate use experience

• DOI: 10.1007/s00277-010-1098-7
• Publication Date: 2010-10-13T20:42:26Z
• Authors: Grzegorz Wladysla...; Wanda Knopinska-P...; Magdalena Matuszak; Elzbieta Kisiel; Dorota Hawrylecka; Anna Szmigielska-...; Donata Urbaniak-K...; Jaroslaw Dybko; Patrycja Zielinska; Anna Dabrowska-Iw...; Joanna Werkun; Piotr Rzepecki; Wiktoria Wroblewska; Wieslaw Wiktor-Je...
• Keywords: Plerixafor; Autologous stem-cell transplantation; CXCR4 antagonist

Recent developments in the field of targeted therapy have led to discovery a new drug, plerixafor, that is specific inhibitor CXCR4 receptor. Plerixafor acts concert with granulocyte colony-stimulating factor (G-CSF) increase number stem cells circulating peripheral blood (PB). Therefore, it has been applied hematopoietic cell mobilization. We analyzed retrospectively data regarding mobilization plerixafor cohort 61 patients suffering from multiple myeloma (N = 23), non-Hodgkin's lymphoma 20), or Hodgkin's 18). At least one previous attempt had failed 83.6% these patients, whereas 16.4% were predicted be poor mobilizers. The median CD34+ PB after first administration was 22/μL (range 0-121). In total, 85.2% proceeded collection, and two 0-4) aphereses performed. A minimum 2.0 × 10(6) per kilogram patient's body weight (cells/kg b.w.) collected 65.6% 2.67 cells/kg b.w. (0-8.0). Of 55.7% already undergone autologous transplantation, time neutrophil platelet reconstitution 12 14 days, respectively. Cases late graft failure not observed. identified diagnosis radiotherapy as independent factors contributed current report demonstrates satisfactory efficacy plus G-CSF for heavily pre-treated